thiethylperazine
Trade name: torecan
Small moleculeapproved
Approved
Jul 18, 1961
Thiethylperazine is a antiemetic, which was used for the treatment of nausea and vomiting in patients undergoing radiotherapy, chemotherapy or as a postoperative care. Thiethylperazine exerts its therapeutic effect by blocking dopamine receptors in brain. The drug is capable of potentiating CNS depressants as well as atropine. — NCATS
Clinical trial activity
4 trials · 5 clinical orgs · 1 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
1
Earliest trial started Nov 24, 2017 (NCT03417986)
Timeline
Indications
Approved for
Studied for
Mechanism of action
- Dopamine D2 receptorANTAGONIST
DRD2 antagonist
Approval history
- approvedJul 18, 1961
Chemistry & pharmacology
Loading structure…
SMILES
CCSC1=CC=C2SC3=CC=CC=C3N(CCCN4CCN(C)CC4)C2=C1- Mol. weight
- 399.616 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Availability
- Discontinued
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaThiethylperazine ↗
- NCATS8ETK1WAF6R ↗
- ChEMBLCHEMBL1378 ↗
- ChEMBLCHEMBL3989478 ↗
- ChEMBLCHEMBL1200856 ↗
- ChEMBLCHEMBL1201074 ↗
- ChEMBLCHEMBL2359670 ↗
Also known as
- 2-(ethylthio)-10-[3-(4-methylpiperazin-1-yl)propyl]-10h-phenothiazine
- 2-(ethylthio)-10-[3-(4-methylpiperazin-1-yl)propyl]-10h-phenothiazine
- ethylthioperazine
- gs-95
- gs-95
- norzine
- norzine
- thiethylperazin
- thiethylperazin
- thiethylperazine
- thiethylperazine
- thiethylperazine
- thiethylperazine
- thiethylperazine
- thiethylperazine
- thiethylperazine
- thiethylperazine
- thiethylperazine
- thiéthylpérazine
- thiéthylpérazine
- thiethylperazine dimalate
- thiethylperazine malate
- thiethylperazine malate
- thiethylperazine malate
- thiethylperazine malate
- thiethylperazine maleate
- thiethylperazine maleate
- thiethylperazine maleate
- thiethylperazine maleate
- thiethylperazinum
- thiethylperazinum
- thietylperazine malate
- thietylperazine malate
- thietylperazine maleate
- thietylperazine maleate
- tietilperazina
- tietilperazina
- torecan
- torecan
- torecan
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06947577 | Phase 4 | May 1, 2024 | Cairo University |
| NCT05920369 | N/A | Apr 15, 2023 | Cairo University |
| NCT03621865 | N/A | Jul 23, 2018 | Naturex SA, Pasteur Merieux |
| NCT03417986 | Phase 2 | Nov 24, 2017 | Immungenetics AG, University of Heidelberg |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cairo University | Academic/Hospital | 2 | 2 | 2 | 2023 |
| Immungenetics AG | For profit | 1 | 1 | 1 | 2017 |
| Naturex SA | For profit | 1 | 1 | 1 | 2018 |
| Pasteur Merieux | For profit | 1 | 0 | 1 | 2018 |
| University of Heidelberg | Academic/Hospital | 1 | 0 | 1 | 2017 |
5 organizations
Page 1 / 1